Correlation Between Molecular Partners and Talaris Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Talaris Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Talaris Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Talaris Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Talaris Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Talaris Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Talaris Therapeutics.

Diversification Opportunities for Molecular Partners and Talaris Therapeutics

-0.06

Correlation Coefficient

Molecular Partners  Talaris Therapeutics

Good diversification

The 3 months correlation between Molecular and Talaris is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Talaris Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Talaris Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Talaris Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Talaris Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Talaris Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Talaris Therapeutics

If you would invest  491.00  in Molecular Partners AG on October 8, 2024 and sell it today you would lose (4.00) from holding Molecular Partners AG or give up 0.81% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	1.61%
Values	Daily Returns

Molecular Partners AG  vs.  Talaris Therapeutics

Molecular Partners

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Talaris Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Talaris Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Talaris Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Molecular Partners and Talaris Therapeutics

The main advantage of trading using opposite Molecular Partners and Talaris Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Talaris Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Talaris Therapeutics will offset losses from the drop in Talaris Therapeutics' long position.

The idea behind Molecular Partners AG and Talaris Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.